Detalhe da pesquisa
1.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32130809
2.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33308425
3.
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.
BMC Health Serv Res
; 21(1): 255, 2021 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-33743684
4.
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
AIDS Behav
; 24(12): 3533-3544, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32447500
5.
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.
AIDS Behav
; 24(12): 3473-3481, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32410051
6.
Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study.
Br J Clin Pharmacol
; 80(5): 1051-63, 2015 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25940675
7.
Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial.
AIDS Res Hum Retroviruses
; 37(3): 207-213, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33323029
8.
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Patient
; 14(6): 849-862, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34056699
9.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet HIV
; 8(11): e679-e689, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34648734
10.
Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial.
HIV Res Clin Pract
; 21(4): 105-113, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33048662
11.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
J Acquir Immune Defic Syndr
; 85(4): 498-506, 2020 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33136751
12.
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
HIV Clin Trials
; 19(4): 129-138, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30445896
13.
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Lancet HIV
; 4(8): e331-e340, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28546090
14.
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Lancet Infect Dis
; 15(10): 1145-1155, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26201299
15.
Yersinia pseudotuberculosis adhesins regulate tissue-specific colonization and immune cell localization in a mouse model of systemic infection.
Infect Immun
; 74(11): 6487-90, 2006 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-16920785
16.
Distinct mechanisms of integrin binding by Yersinia pseudotuberculosis adhesins determine the phagocytic response of host macrophages.
Cell Microbiol
; 7(10): 1474-89, 2005 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-16153246